Finland: Forendo Pharma acquired by Organon for up to US$954m

Forendo Pharma, a Finland-based clinical-stage drug development company focused on women’s health, has been acquired by global women’s healthcare company, Organon, for up to US$954m. The transaction includes an upfront payment of US$75m, the assumption of US$9m in Forendo debt, payments linked to development and regulatory milestones of up to US$270m, and a further potential…

You must be a HMI Subscriber to view this content.

Subscribe Now »